Group 1 - The KDIGO 2026 Clinical Practice Guideline Draft for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) has been published, marking the first major update since 2012, focusing on early detection and risk prediction [1][2] - The new guidelines emphasize the continuum of AKI and AKD, highlighting the need for precise diagnosis using functional measures and structural biomarkers, along with improved clinical decision support tools [2][3] - KDIGO's updated framework reflects a global shift towards earlier identification and intervention in acute kidney disorders, which is seen as a significant advancement for clinicians and patients [3] Group 2 - BioPorto A/S specializes in in vitro diagnostics, focusing on actionable biomarkers to enhance patient management and improve clinical outcomes [4][5] - The company's flagship products utilize the NGAL biomarker to aid in the risk assessment and diagnosis of AKI, allowing for faster identification of at-risk patients compared to standard care [5] - BioPorto's NGAL tests are marketed under applicable registrations, including CE mark, in various countries worldwide [5]